Lizhu, Hengrui, Beida Nine innovative drugs have a great future! Who can enter the catalogue of Chinese listed chemicals?

Highlights Recently, CDE released the first batch of varieties included in the catalogue of chemical drugs on the market in China, and solicited opinions from the public This time, 119 products and 185 product specifications entered the first batch of catalogue, including 9 innovative drugs of 8 domestic enterprises, i.e alamod tablets of Xiansheng pharmaceutical, eplazol enteric coated tablets of Lizhu group, arixib tablets and methanesulfonic acid of Hengrui pharmaceutical Apatinib tablets, beta pharmaceutical ektinib hydrochloride tablets, etc Who can finally enter the catalogue of Chinese listed chemicals? Table: data sources of nine innovative drugs (ranking in no particular order) to be included in the first batch of varieties included in the catalogue of Chinese listed chemicals: CDE, minenet database note: in 2016, products with terminal sales of less than 20 million yuan in China's public medical institutions were not included in the statistics Ailamode, which was launched in 2011, is a class 1.1 new drug of Xiansheng pharmaceutical for the treatment of rheumatoid arthritis According to the data of mienei.com, in 2016, the sales of alamodex in the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) reached 89.72 million yuan, an increase of 32.94% year on year The product entered the new national medical insurance catalogue in February this year, and is expected to be sold in large quantities in the future Liprazole enteric coated tablets, developed by liprazole group and approved by CFDA for listing in December 2007, is a powerful ion pump inhibitor, which has applied for invention patents in China, the United States, the European Union and other countries In 2016, the terminal sales of China's public medical institutions reached 378 million yuan This product has become a new growth point of Lizhu group's performance and a heavyweight product in the digestion field Irixib tablet, apatinib mesylate tablet, Hengrui medicine irixib is a new drug jointly developed by Hengrui and the Institute of medicine of Chinese Academy of Medical Sciences, which is used to treat osteoarthritis and rheumatoid arthritis In 2016, the terminal sales of China's public medical institutions reached 89.66 million yuan, which has a significant competitive advantage in the field of anti-inflammatory and analgesic drugs Apatinib is a class 1.1 new drug independently developed by Hengrui It was approved by CFDA in October 2014 for the treatment of advanced gastric cancer In 2016, the terminal sales of public medical institutions in China exceeded 300 million yuan In addition to gastric cancer, indications in other tumor areas such as lung cancer and liver cancer are also in clinical research With the continuous expansion of indications, this variety will become a new growth point of Hengrui's performance In December 2014, sidabamide tablet, a micro core organism in Shenzhen, was approved by CFDA for marketing to treat peripheral T-cell lymphoma It is a subtype selective histone deacetylase inhibitor, which can activate the anti-tumor cell immune function of patients, effectively inhibit tumor cells, and prolong the life of cancer patients Moroxynidazole and sodium chloride injection Jiangsu Haosen Pharmaceutical Co., Ltd moroxynidazole and sodium chloride injection are systemic antibacterials, which were approved to be listed in 2014 They are the exclusive products of Jiangsu Haosen Pharmaceutical Co., Ltd and have twice won the national science and technology major special projects Melinda is a new generation of the third generation of nitroimidazoles Compared with previous generations of nitroimidazoles, this product has strong antibacterial activity, quick onset, good tolerance and higher safety In July 2017, the Ministry of human resources and social security of the people's Republic of China issued a document confirming that 36 drugs including mylinda will be included in the category B scope of the new medical insurance catalogue Nanofloxacin malate capsule Zhejiang medicine nanofloxacin malate capsule is a systemic antibacterial drug approved for marketing in 2016 and is the exclusive product of Zhejiang medicine Nanofloxacin malate capsule is a new generation of fluoroquinolones free drug Its antibacterial spectrum covers the common pathogenic microorganisms that cause community acquired pneumonia (CAP) Compared with other fluoroquinolones, the product has strong antibacterial activity against penicillin and quinolones resistant Streptococcus pneumoniae and methicillin resistant Staphylococcus aureus (MRSA) Antofloxacin hydrochloride tablets Anhui Global Pharmaceutical Co., Ltd Antofloxacin hydrochloride tablets are systemic antibacterial drugs approved for marketing in 2009, and are the exclusive products of Anhui Global Pharmaceutical Co., Ltd Compared with other quinolones, the innovation of the product lies in the minimum phototoxicity, small cardiac toxicity, long biological half-life, wide antibacterial spectrum, stronger antibacterial activity, wide tissue distribution, good absorption, high bioavailability, good safety, etc In 2016, the total sales volume of Anhui global pharmaceutical in China's public medical institutions was 165 million yuan, which contributed 14.78% of the company's performance Etinib hydrochloride BEDA Pharmaceutical Co., Ltd etinib hydrochloride is an anti-tumor drug approved for marketing in 2011, and is the exclusive product of BEDA Pharmaceutical Co., Ltd The product is a new targeted biological agent, which is a powerful and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor In 2012, exetane was listed in citeline's annual new drug catalog, which is the first Chinese independently developed drug to be listed in the catalog This product is the top 20 brand of anti-tumor drugs for public medical institutions in China in 2016, with a sales volume of 740 million yuan.